Stay updated on ARIEL4 Rucaparib vs Chemotherapy in BRCA Mutant Ovarian Clinical Trial

Sign up to get notified when there's something new on the ARIEL4 Rucaparib vs Chemotherapy in BRCA Mutant Ovarian Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ARIEL4 Rucaparib vs Chemotherapy in BRCA Mutant Ovarian Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to the comparison of efficacy and safety between rucaparib and chemotherapy for the treatment of relapsed ovarian cancer in patients with a deleterious BRCA1/2 mutation.
    Difference
    0.1%
    Check dated 2024-06-06T14:39:29.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The webpage has updated the 'Participation Criteria' section to provide detailed eligibility criteria for participants, including age, diagnosis, and prior treatments, replacing the previous placeholder text.
    Difference
    12%
    Check dated 2024-05-22T21:03:25.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:29:41.000Z thumbnail image

Stay in the know with updates to ARIEL4 Rucaparib vs Chemotherapy in BRCA Mutant Ovarian Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ARIEL4 Rucaparib vs Chemotherapy in BRCA Mutant Ovarian Clinical Trial page.